**COVID-19 Oral Antivirals Update 1-7-22:**

* **Supply:** We now have molnupiravir in stock. We are currently out of Paxlovid, though hope to have more soon.
* **Allocation:** We are following the state’s request issued 1/4/22 to limit dispensing to patients at highest risk of severe disease (NIH tiers 1 & 2) as supply is currently limited. The announcement from the state follows but essentially includes **immunocompromised** patients and **unvaccinated, high-risk** patients *only*.
* **Prescriptions:** We request that prescriptions for either medication include:
	+ Symptom onset date (both medications must be started within 5 days of sx onset)
	+ Date of positive COVID test
	+ What qualifies the patient as high-risk
* **Oral antiviral differences:** A comparison chart we created on the two antivirals follows. Molnupiravir is not recommended in pregnancy or in children. Paxlovid has many significant drug-interactions and contraindications.
* **Med Lists:** Due to Paxlovid’s drug-interactions, it would be helpful to receive a current medication list when this agent is prescribed so that we may appropriately counsel the patient.
* **Patient procedure:** Please ask patients to remain in their car, wear a face mask and call us when they arrive. One of our pharmacists will spend adequate time counseling each patient.
* **Cost:** Though insurance is not yet paying anything for these medications, we are dispensing them to patients at no charge.
* **Documents that follow:**
	+ *Patient Prioritization for COVID-19 Therapeutics:* lists eligible patients in NIH tiers 1&2
	+ *COVID-19 High Risk Medication Conditions:* lists conditions classified as high-risk
	+ *Molnupiravir Checklist Tool for Prescribers:* FDA document for appropriate prescribing

We appreciate your help during these challenging times. Please do not hesitate to reach out to us with any questions or concerns!

Jessi Stout, PharmD